Đang chuẩn bị liên kết để tải về tài liệu:
Clinical markers of immunotherapy outcomes in advanced sarcoma
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Despite immunotherapy’s promise in oncology, its use for sarcoma remains challenging. There are no sarcoma-specific biomarkers for immune checkpoint inhibitors (ICI). Previously, we reported our institutional experience highlighting ICI activity in 29 patients with sarcoma. |